>> My name is Eric Hall II, and I work in the pharmaceutical biotechnology industry.
I lead up a team that is responsible for generating clinical and economic evidence
to support access and reimbursement for our products in the marketplace.
So, I think at the end of the day, our responsibility is to essentially generate
and establish the value proposition for a given therapy.
And so, that's leveraging both quantitative and qualitative data and information
that tells the story, if you will.
Most people are familiar with RCTs and randomized clinical trials
to demonstrate the safety and efficacy of a product, but it really goes far beyond
that in terms of delivering value to stakeholders out in the marketplace.
So, one of the things that we're focused on right now is continuing
to demonstrate the overall healthcare resource utilization and costs
within a given condition, called Spinal Muscular Atrophy.
So that's SMA.
It's a condition in which is a high unmet medical need.
There haven't been therapies in the marketplace previously, and so the ownness is on us
to demonstrate, okay, what are the total direct medical costs for this condition,
and also continuing to build the overall humanistic side of the value equation
in capturing patient outcomes, the impact on caregiver burden, the patients themselves,
and also capturing quality of life and, you know, work productivity and school absenteeism,
and these additional factors that often go unnoticed.
And along with the out-of-pocket costs in which patients and their families have to spend
with respect to their condition, that often aren't captured
because insurance is not necessarily covering those, and that can be substantial
in this condition, with respect to modifications to their homes, having to purchase new vehicles,
as well as durable medical equipment for the patients.